Why the Dip in Cassava Sciences (SAVA) Stock Shouldn’t Spook You

Investors did not like the latest update from Alzheimer’s drug maker Cassava Sciences (NASDAQ:SAVA). After showing excellent results from the first 50 patients treated with simufilam, the company’s prospective Alzheimer’s drug in an open-label mid-stage study, the results from the full 200+ patients were not as good.

Patients were given 2 100mg tablets a day over the course of one year on average, and these exhibited only a minimal change in the ADAS-Cog score. In the clinical research of…

Read More